Table 3.
Bioanalytical methods and condition's differences between previous studies.
| No. | Analysis Condition | Harahap et al. (2020) [40] | Carmella, Chen, Zhang, Zhang, Hatsukami, & Hecht, (2007) [41] | Yan, Byrd, Brown, & Borgerding, (2010) [42] |
|---|---|---|---|---|
| 1 | Subject | 17 breast cancer patients with cyclophosphamide chemotherapy regimens | 35 smokers and 21 orang non-smokers | 1 smoker and 2 non-smokers |
| 2 | Instrument type | Triple quadrupole LC-MS/MS, positive ion ESI | Triple quadrupole LC-APCI-MS/MS-SRM, negative APCI | LC-MS/MS, negative ion ESI |
| 3 | Mobile phase | 0,1% formic acid in water (A) - 0,1% formic acid in acetonitrile (90:10 v/v) (B) | 15 mM Acetic ammonium (NH4OAc) (A) – methanol (MeOH) (B) | 10 mM Ammonium formate in water (A) – acetonitrile (B) |
| 4 | Column | Acquity® BEH C18 (2,1 × 100 mm; 1,7 μm) | Synergi Max-RP C12 (4,6 mm × 25 cm; 4 μm) | Phenomenex HILIC (100 × 2 mm; 3 μm) |
| 5 | Flow rate | 0,2 ml/min | 0,8 ml/min | 1,0–1,2 ml/min |
| 6 | Elution method | Gradient | Gradient | Gradient |
| 7 | Detection method | m/z 222,10 > 90,97 and 164,10 > 122,02 for 3-HPMA and NAC | m/z 220 > 91 for 3-HPMA, m/z 223 > 94 for [13C3]3-HPMA, and m/z 237 > 105 for injection standard | m/z 220,2 > 91,1 and 223,2 > 91,1 for 3-HPMA and 3-HPMA d3 |
| 8 | Sample preparation method | Dilution and acidification with formic acid | Solid phase extraction with 2% ammonium hydroxide (NH4OH) and methanol | Dilution with ammonium formate |
| 9 | Obtained LLOQ | 40,0 ng/ml | 0,9 ng/ml | 22,0 ng/ml |
List of abbreviations: LC-MS/MS: Liquid chromatography-tandem mass spectrometry; ESI: Electrospray ionization; LC-APCI-MS/MS-SRM: Liquid chromatography coupled with atmospheric pressure chemical ionization and selected reaction monitoring mass spectrometry; 3-HPMA: 3-Hydroxypropyl mercapturic acid; LLOQ: Lower limit of quantification.